An Interest In:
Web News this Week
- April 18, 2024
- April 17, 2024
- April 16, 2024
- April 15, 2024
- April 14, 2024
- April 13, 2024
- April 12, 2024
Some of Our Sources
- Engadget
- Mashable
- Simplebits
- TutsPlus - Code
- Spoon Graphics
- Smashing Apps
- Specky Boy
- Android Headlines
- Daily Now
- Hashedout
Help Webnuz
Referal links:
July 22, 2013 09:08 pm GMT
Autism, the disorder that affects social skills and communication and that is seeing a rising number of diagnoses, has a myriad number of causes from genetic to environmental factors. Because it’s largely behavioral, it may not be formally diagnosed until a child is few years old, preventing much-needed early intervention and care. But a Massachusetts-based startup SynapDx is hoping to change that by combining advanced bioinformatics, genome sequencing and blood tests in a way that may help parents diagnose their children at a much earlier age. The company just closed a $15.4 million round led by Google Ventures to develop a blood test for the disorder, by studying the genetic make-up of children that are clinically diagnosed with the condition. The more the company can understand about different genetic mutations that are associated with autism, the more accurate a blood test they can create to signal for the disorder. “We don’t know what the root causes of autism are, but we can correlate what we see in the blood with clinical diagnoses,” said Theresa Tribble, the vice president of commercial strategy for the company. “We hope to collaborate with researchers to give us additional insight to what those causes are.” The end goal isn’t to create a bulletproof blood test for autism, but to create an early-stage test that can help parents refer their children for a full medical diagnosis earlier on. “This is more of a risk assessment,” she said. “The goal is to help pediatricians identify children who should be referred for a full clinical evaluation earlier than they do today.” She added that the average age of diagnosis is around 4 1/2 years, but parents often become worried at around 18 months. “That’s a really long lag,” she said. Foundation Medical Partners also joins as a new investor along with earlier investors North Bridge Venture Partners and General Catalyst Partners. With the round, Googles Andrew Conrad, who is the former chief scientific officer of LabCorp and co-founder of the National Genetics Institute, will join the board. Google Ventures’ Krishna Yeshwant, who leads many of the firm’s health and medical investments, did this deal. While SynapDx is solely focused on autism today, one could imagine that they could apply their techniques to other disorders later on. “There continue to be broad unmet needs in objective genomics tests for neurodevelopment disorders, so that would be a natural expansion point,”
Original Link: http://feedproxy.google.com/~r/Techcrunch/~3/cTZv79kMrTA/
SynapDx Raises $15.4M In Quest To Create A Blood Test For Autism
Autism, the disorder that affects social skills and communication and that is seeing a rising number of diagnoses, has a myriad number of causes from genetic to environmental factors. Because it’s largely behavioral, it may not be formally diagnosed until a child is few years old, preventing much-needed early intervention and care. But a Massachusetts-based startup SynapDx is hoping to change that by combining advanced bioinformatics, genome sequencing and blood tests in a way that may help parents diagnose their children at a much earlier age. The company just closed a $15.4 million round led by Google Ventures to develop a blood test for the disorder, by studying the genetic make-up of children that are clinically diagnosed with the condition. The more the company can understand about different genetic mutations that are associated with autism, the more accurate a blood test they can create to signal for the disorder. “We don’t know what the root causes of autism are, but we can correlate what we see in the blood with clinical diagnoses,” said Theresa Tribble, the vice president of commercial strategy for the company. “We hope to collaborate with researchers to give us additional insight to what those causes are.” The end goal isn’t to create a bulletproof blood test for autism, but to create an early-stage test that can help parents refer their children for a full medical diagnosis earlier on. “This is more of a risk assessment,” she said. “The goal is to help pediatricians identify children who should be referred for a full clinical evaluation earlier than they do today.” She added that the average age of diagnosis is around 4 1/2 years, but parents often become worried at around 18 months. “That’s a really long lag,” she said. Foundation Medical Partners also joins as a new investor along with earlier investors North Bridge Venture Partners and General Catalyst Partners. With the round, Googles Andrew Conrad, who is the former chief scientific officer of LabCorp and co-founder of the National Genetics Institute, will join the board. Google Ventures’ Krishna Yeshwant, who leads many of the firm’s health and medical investments, did this deal. While SynapDx is solely focused on autism today, one could imagine that they could apply their techniques to other disorders later on. “There continue to be broad unmet needs in objective genomics tests for neurodevelopment disorders, so that would be a natural expansion point,”Original Link: http://feedproxy.google.com/~r/Techcrunch/~3/cTZv79kMrTA/
Share this article:
Tweet
View Full Article
Techcrunch
TechCrunch is a leading technology blog, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech news.More About this Source Visit Techcrunch